Anti-tumor compound and preparation method and use thereof

1. A compound of general formula (III-E) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein R 1 is selected from the group consisting of: —O—, —(R 2 )N— and —S—;

X is -L 1 -CH 2 —C(O)—;

L 1 is —(C(R 3a )(R 3b )) m —;

wherein R 2 is hydrogen, or a C 1-6 aliphatic group optionally substituted with R; each R 3a and each R 3b are independently hydrogen, protium, deuterium, tritium, halogen, —NO 2 , —CN, —OR, —SR, or a C 1-6 aliphatic group optionally substituted with R;

wherein R is hydrogen, protium, deuterium, tritium, halogen, —NO 2 , —CN, —OH, —SH, or —NH 2 ;

m is selected from the group consisting of integers from 1 to 5, and R 3a and R 3b are not both hydrogen in each —C(R 3a )(R 3b )—.

2. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 1, and L 1 is —C(R 3a )(R 3b )—.

3. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 2, and L 1 is —(C(R 3a )(R 3b )) 2 —.

4. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3a is a C 1-6 aliphatic group.

5. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3b is hydrogen or a C 1-6 aliphatic group.

6. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3a is a C 1-6 aliphatic group, and R 3b is hydrogen.

7. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3a is methyl, and R 3b is hydrogen.

8. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3a is a C 1-6 aliphatic group, and R 3b is a C 1-6 aliphatic group.

9. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3a is methyl, and R 3b is a C 1-6 aliphatic group.

10. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 3a is methyl, and R 3b is methyl.

11. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 1 is —(R 2 )N— or —S—, and R 2 is hydrogen or a C 1-6 aliphatic group.

12. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R 1 is —O—.

13. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 1 , wherein R is hydrogen.

14. A compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound comprises the structures selected from the group consisting of:

15. A compound of general formula (III-F) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein, L x is

wherein R 1 is selected from the group consisting of: —O—, —(R 2 )N— and —S—;

X is -L 1 -CH 2 —C(O)—;

L 1 is —(C(R 3a )(R 3b )) m —;

wherein R 2 is hydrogen or a C 1-6 aliphatic group optionally substituted with R, each R 3a and each R 3b are independently hydrogen, protium, deuterium, tritium, halogen, —NO 2 , —CN, —OR, —SR, or a C 1-6 aliphatic group optionally substituted with R;

wherein R is hydrogen, protium, deuterium, tritium, halogen, —NO 2 , —CN, —OH, —SH, or —NH 2 ;

m is selected from the group consisting of integers from 1 to 5, and R 3a and R 3b are not both hydrogen in each —C(R 3a )(R 3b )—.

16. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 15 ,

wherein L x is

R 1 is selected from the group consisting of: —O—, —(R 2 )N— and —S—;

X is -L 1 -CH 2 —C(O)—;

L 1 is —(C(R 3a )(R 3b )) m —, m is 1 or 2, and R 3a and R 3b are not both hydrogen in each —C(R 3a )(R 3b )—;

wherein each R 2 , each R 3a and each R 3b is independently hydrogen, halogen, or a C 1-6 aliphatic group which is optionally substituted with R;

wherein each R is hydrogen or halogen.

17. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to any one of claim 15 , wherein the compound comprises the structures selected from the group consisting of:

18. A pharmaceutical composition, comprising the compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier.

19. A method for treating a tumor, comprising administering to a subject in need with the compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , and/or a pharmaceutical composition that comprise the same.

20. The method according to claim 19 , wherein the tumor is selected from the group consisting of: lung cancer, kidney cancer, urinary tract carcinoma, colorectal cancer, prostatic cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer and esophageal cancer.